NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01310894,Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.,https://clinicaltrials.gov/study/NCT01310894,PCM301,COMPLETED,"The aims of this study are:

* to assess the impact of TOOKAD® Soluble-Vascular Targeted Photodynamic Therapy (VTP) on the rate of absence of definite cancer using patients on active surveillance as a comparison (co-primary objective A) and
* to determine the difference in rate of treatment failure associated with observed progression of disease from low risk prostate cancer to moderate or higher risk prostate cancer in men who undergo TOOKAD® Soluble-VTP compared to men on active surveillance (co-primary objective B).",NO,Prostate Cancer,DRUG: TOOKAD® Soluble,"Co-primary endpoint 'A': Rate of absence of definite cancer using patients on active surveillance as a comparison., Histological changes are assessed using biopsies or any other pathology result obtained during the study planned or not., Month 24|Co-primary endpoint 'B': Difference in rate of treatment failure associated with observed progression of disease from low risk prostate cancer to moderate or higher risk prostate cancer., Moderate or higher risk is defined as the observation of:

* More than 3 cores positive for cancer when considering all histological examination available during follow-up of study;
* or any Gleason primary or secondary pattern 4 or more;
* or at least one cancer core length greater than 5 mm;
* or PSA\>10ng/mL ( in 3 consecutive measures);
* or any T3 prostate cancer,
* or metastasis;
* or prostate cancer related death, Over 24 months follow-up.","The rate of additional prostate cancer radical therapy, Number of patients undergoing a radical treatment for prostate cancer such as: radical prostatectomy, radiotherapy, brachytherapy divided by the total number of patients., Over 24 months follow-up|Total number of cores positive for cancer, Total number of biopsy sample containing tumor cells at the month 24 biopsy, Month 24|The rate of incontinence, erectile dysfunction, urinary symptoms, Number of patients experiencing urinary incontinence, erectile dysfunction or urinary symptoms events divided by the total number of patients., Randomisation visit, Day 7 after VTP , Month 3, Month 6, Month 9, Month 12, Month 24|The rate of adverse events, Number of patients experiencing adverse events divided by the total number of patients., Screening-Month 24|The rate of severe prostate cancer related events: cancer extension to T3, metastasis and prostate cancer related death, Number of patients experiencing severe prostate cancer related events: cancer extension to T3, metastasis and prostate cancer related death divided by the total number of patients., Screening-Month 24|The overall quality of life will be recorded for potential utility and descriptive studies., Results of the International Index of Erectile Function (IIEF) and International Prostate Symptoms Score (IPSS) patients questionaires., Randomisation visit; Month 12; Month 24",,Steba Biotech S.A.,,MALE,"ADULT, OLDER_ADULT",PHASE3,413,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CLIN1001 PCM301,2011-02,2015-06,2015-08,2011-03-09,,2019-07-11,"Dept. of Urology-University Hospitals Leuven, Leuven, 3000, Belgium|Department of Urology-Tampere University Hospital-, Tampere, 33521, Finland|Service d'Urologie - Centre Hospitalier Universitaire d'Angers, Angers, 49933, France|CHRU Hopital Jean Minjoz, Besançon, 25030, France|Site Médipole, Cabestany, 66330, France|Polyclinique Sévigné, Cesson Sévigné, 35512, France|Clinique d'Urologie et de Transplantation Rénale CHU Grenoble, Grenoble, 38043, France|Hôpital Claude Huriez, Lille, 59037, France|Hôpital La Conception, Marseille, 13005, France|Clinique Ambroise Paré, Neuilly sur Seine, 92200, France|Institut Mutualiste Montsouris (IMM), Paris Cedex 14, 75674, France|Hôpital Cochin, Paris Cedex 14, 75679, France|Hôpital Tenon, Paris, 75020, France|Institut Mutualiste Montsouris (IMM), Paris, 75674, France|Centre Hospitalier Universitaire Lyon Sud, Pierre-Bénite, 69495, France|Polyclinique les Bleuets, Reims, 51100, France|CHU Pontchaillou, Rennes, 35 033, France|Clinique Urologique Nantes, Saint Herblain, 44800, France|Hôpital Foch, Suresnes, 92150, France|Centre Hospitalier Universitaire de Rangueil, Toulouse, 31403, France|Marien Krankenahaus GmbH, Bergisch Gladbach, 51465, Germany|ATURO-Gemeinschaftspraxis für Urologie und Andrologie, Berlin-Wilmersdorf, D-14197, Germany|Klinikum Braunschweig, Braunschweig, 38126, Germany|Universitätsklinikum ""Carl Gustav Carus"" der Technischen Universität, Dresden, D-01307, Germany|Urologische Gemeinschaftspraxis, Emmendingen, 79132, Germany|Martini-Klinik am UKE Hamburg-Eppendorf Prostate Cancer Center, Hamburg, D-20246, Germany|Vinzenz Krankenhaus - Department of Urology, Hannover, 30559, Germany|SLK-Kliniken Heilbronn GmbH, Heilbronn, 74078, Germany|University Hospital Schleswig-Holstein, Kiel, D-24105, Germany|Ludwig-Maximilians-Universität München, Munich, D - 81377, Germany|Urologie 24, Nuremberg, 90491, Germany|Unità Operativa Urologia Lucca - c/o Azienda USL 2 - Ospedale Campo di Marte, Lucca, 55100, Italy|Unità di Chirurgia Urologica Mininvasiva, Roma, 00189, Italy|Unità Operativa Urologica di Savona, Ospedale San Paolo di Savona, Savona, 17100, Italy|Osp. S. Giov. Battista Molinette-Dipartimento di Discipline Medico-Chirurgiche Urologia, Torino, 10126, Italy|Netherlands Cancer Institute, Amsterdam, 1066 CX, Netherlands|Polikliniek Urologie-Catharina Ziekenhuis, Eindhoven, 5623 EJ, Netherlands|Hospital Universitari de Bellbitge-Servico de Urologia, L'Hospitalet de Llobregat, Barcelona, 08907, Spain|Hospital Universitario de A Coruña, A Coruña, 15006, Spain|Fundacio Puigvert-Department of Urology, Barcelona, 08025, Spain|Hospital Vall d'Hebron, Barcelona, 08035, Spain|Department of Urology-Hospital Clinic, University of Barcelona, Barcelona, 08036, Spain|Hospital 12 de Octubre - Departmento de Urologia, Madrid, 28041, Spain|Complejo Hospitalario Regional Virgen Del Rocio-Department Urology, Sevilla, 41013, Spain|Instituto Valenciano de Oncologia, Valencia, 46009, Spain|Dept of Urology-University Hospital-, Malmö, 20502, Sweden|Anna-Seiler-Haus Inselspital, Bern, CH-3010, Switzerland|Kings College Hospital (KCH), London, SE5 9RS, United Kingdom|University College of London Hospital, London, United Kingdom|Oxford John Radcliffe Hospital Trust, Oxford, OX3 7LJ, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom",
